Endometriosis occurs when tissue similar to that normally found in the uterus begins to grow outside of the uterus, leading to a range of symptoms, including painful periods, pelvic pain in between periods and pain with sex. These growths are called lesions and can occur on the ovaries, the fallopian tubes or other areas near the uterus, such as the bowel or bladder. Estrogen fuels the growth of lesions.
According to researchers, 7.5 million women in the United States are diagnosed with endometriosis, with 3 million diagnosed with moderate to severe endometriosis.
In collaboration with AbbVie, Neurocrine Biosciences has a novel, oral treatment approved for the management of moderate to severe endometriosis pain. AbbVie is responsible for all development, marketing and commercialization costs.